Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 15 (14) |
| Completed vs Stopped Early | 1 / 5 (17.2%) |
| Median Closed Actual Enrollment | 34 participants |
| Physical Hospital Site Disclosure | 28.1% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 11 |
| Nanfang Hospital of Southern Medical University | Guangzhou, Guangdong | 6 |
| MD Anderson Cancer Center | Houston, TX | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06319456 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | Phase III | RECRUITING |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Ascentage Pharma Group Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.